PDCD1 and cancer: It is known that the lack of T‐cell infiltration in TME impairs the therapeutic effect of PD‐1 checkpoint blockade.[32] Particularly, RT can also enhance checkpoint blockade immunity.[33] In our work, this augmented RT‐RDT and PD‐1 checkpoint blockade combinatory X‐ray nanoprocessor platform greatly improves cancer therapeutic outcomes, resulting in several antitumor immunities.